Table 4. Comparative results of eficacy and survival of Phase II study47 of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB NSCLC.
| EFFICACY | Number of patients | % Stage IIIB | Response rate after induction CT (CR+PR) | Global response after CT-RT (CR+PR) | Progression free survival (months) | Mean survival (months) | 1-year Survival (%) | 3-year Survival (%) |
| VRL + CDDP | 65 | 60% | 40% | 69% | 11,5 | 17,7 | 65 | 23 |
| PTX + CDDP | 58 | 48% | 31% | 66% | 9,1 | 14,8 | 62 | 19 |
| GEM + CDDP | 62 | 37% | 35% | 68% | 8,4 | 18,3 | 68 | 28 |
CT: chemotherapy; CT-RT: chemotherapy concomitant with radiotherapy; CR+PR: complete response and partial response; VRL + CDDP: cisplatin with vinorelbine; PTX + CDDP: cisplatin with paclitaxel; GEM + CDDP: cisplatin with gemcitabine